Researchers at the Cleveland Clinic have uncovered a significant link between bacteria present in tumors and the resistance to immunotherapy in patients with head and neck cancer. Two studies published in Nature Cancer show that elevated bacterial levels in the tumor microenvironment can suppress the immune response, resulting in treatment resistance for patients with head and neck squamous cell carcinoma.
The studies, led by Timothy Chan, M.D., Ph.D., chair of the Department of Cancer Sciences, emphasize a shift in focus from just tumor genetics to include the less expected influence of the tumor microbiome on treatment outcomes. “By identifying bacteria as a key barrier to treatment, we’re opening the door to new strategies for patient selection and targeted antibiotic therapies,” Dr. Chan stated.
In the first study, Daniel McGrail, Ph.D., analyzed genetic data from patient tumor samples. His research revealed that higher levels of bacteria—not specific strains—were linked to a weakened immune response. This finding was further validated by Natalie Silver, M.D., M.S., who conducted preclinical tests showing that antibiotics not only reduced tumor size but also enhanced immune response. Conversely, introducing bacteria into tumors led to resistance against immunotherapy.
The research team also collaborated with Renata Ferrarotto, M.D., from the University of Texas MD Anderson Cancer Center, to investigate the relationship between bacterial presence and treatment responses in clinical trial samples. Dr. Silver emphasized the importance of this research, stating, “Our research examines how bacteria influence treatment failure, helping us to identify patients most likely to benefit from immunotherapy.” This approach aims to minimize unnecessary risks and exposures while improving treatment efficacy.
In the second study, Dr. Chan analyzed data from the Javelin HN100 Phase III clinical trial, which tested the addition of anti-PDL1 immunotherapy to standard chemoradiotherapy for patients with head and neck squamous cell carcinoma. The analysis confirmed that patients exhibiting high levels of tumor bacteria experienced poorer outcomes with immunotherapy compared to those receiving standard treatment alone. This trial engaged collaborators from Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute.
The two studies collectively revealed that elevated bacterial levels in tumors attract neutrophils, which are white blood cells crucial for fighting infections. While neutrophils play an essential role in combating bacterial infections, they can also inhibit the immune responses required for effective immunotherapy. These findings set the stage for future research into the reasons behind bacterial attraction to tumors and how to potentially modify this dynamic to enhance treatment effectiveness.
Building on these discoveries, Dr. Silver has initiated a clinical trial aimed at determining whether antibiotics can lower tumor microbiome levels and subsequently boost the immunotherapy response in patients with head and neck squamous cell carcinoma. Meanwhile, Dr. McGrail is investigating how bacteria may influence cancer development and why certain tumors host more bacteria, with the goal of crafting innovative therapeutic strategies. Dr. Chan is also exploring how bacteria might induce DNA mutations in tumors.
“By uncovering the tumor microbiome’s role in immunotherapy resistance, these studies mark a significant step forward in understanding the complex interactions between cancer and the immune system,” Dr. McGrail remarked. “This research broadens our perspective on cancer treatment and paves the way for developing personalized therapies to improve outcomes for patients.”
The implications of these findings could reshape how clinicians approach treatment for head and neck cancer, potentially leading to more effective interventions tailored to individual patient needs.
